Inverse, protean, and ligand-selective agonism: Matters of receptor conformation by Kenakin, Terry
Inverse, protean, and ligand-selective agonism: matters
of receptor conformation
TERRY KENAKIN
Department of Receptor Biochemistry, Glaxo SmithKline Research and Development, Research
Triangle Park, North Carolina 27709, USA
ABSTRACT Concepts regarding the mechanisms by
which drugs activate receptors to produce physiological
response have progressed beyond considering the re-
ceptor as a simple on-off switch. Current evidence
suggests that the idea that agonists produce only vary-
ing degrees of receptor activation is obsolete and must
be reconciled with data to show that agonist efficacy has
texture as well as magnitude. Thus, agonists can block
system constitutive response (inverse agonists), behave
as positive and inverse agonists on the same receptor
(protean agonists), and differ in the stimulus pattern
they produce in physiological systems (ligand-selective
agonists). The molecular mechanism for this seemingly
diverse array of activities is the same, namely, the
selective microaffinity of ligands for different confor-
mational states of the receptor. This paper reviews
evidence for the existence of the various types of
agonism and the potential therapeutic utility of differ-
ent agonist types.—Kenakin, T. Inverse, protean, and
ligand-selective agonism: matters of receptor confor-
mation. FASEB J. 15, 598–611 (2001)
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NEW MOLECULAR TARGETS FOR DRUG
DISCOVERY
The past decade has brought an explosion of new in-
formation about G-protein-coupled receptors (GPCRs),
their nature, and how they behave. With the sequenc-
ing of the human genome will come a plethora of new
GPCR targets. This alliance of information is leading to
a revolution in the drug discovery process. Similarly,
there is a burgeoning number of chemical targets for
therapeutic advantage; the list of drug targets for
receptors has grown considerably (see Fig. 1). Before
1995, the major targets for drug development were full
and partial agonists and antagonists. Since the princi-
pal mode of high-throughput screening has been ra-
dioligand binding, orthosteric ligands (those that steri-
cally hinder the access of the radiolabel to the receptor
binding site) primarily were discovered. Allosteric li-
gands (those that affect receptor function through
binding to their own binding site separate from that of
the endogenous ligand) were detected only if the
allosteric interaction resulted in an alteration of the
affinity of the receptor for the radiolabel. With the
technological advances enabling high-throughput func-
tional receptor screens should come an increase in the
types of GPCR ligands in the new millennium. This will
result in an increase in the number of allosteric ligands
(modulators, agonists, enhancers) that modify receptor
function without necessarily modifying steric access of
the endogenous ligands to the receptor. Therefore, the
changing mode of high-throughput screening can be
predicted to lead to an increase in the texture of drug
types for GPCRs. Another reason for the increasing
number of drug targets is increased knowledge of
GPCR behavior in cellular systems. This has led to the
discovery of inverse agonism. This review will concen-
trate on a subset of these new chemical targets, namely,
those that possess efficacy, either positive or negative,
and these will be discussed in terms of their mecha-
nisms of action and possible relevance to therapy of
disease.
Drugs with ‘efficacy’
Drugs can be thought of as having two properties with
respect to biological systems: affinity for the receptor
and intrinsic efficacy. A common usage of the word
efficacy in clinical pharmacology is ‘therapeutically
useful activity’. Thus, a drug is considered ‘efficacious’
if it alleviates the symptoms of a disease in a patient.
Within this context, even a competitive antagonist
would have ‘efficacy’. This review will discuss efficacy in
terms of its formal definition in pharmacological recep-
tor theory, that is, the property of a molecule that
causes it to produce some observable physiological
response. In terms of GPCRs, a useful working defini-
tion of receptor is the property of a molecule that
causes the receptor to change its behavior toward the
host system (1).
Three types of efficacious drugs will be discussed.
Inverse agonists are an established drug class and
possess what is termed ‘negative efficacy’. Protean
agonists are a theoretical class that produce receptor
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activation of lower magnitude than that emanating
from spontaneous receptor constitutive activity. The
predicted behavior for this class would be the observa-
tion of positive agonism in some GPCR systems and
inverse agonism in others. Although this has been
observed experimentally, an explanation of the effect
in terms of receptor conformation is still theoretical.
Finally, ‘ligand-specific’ agonism, which considers that
some agonists have a different quality as well as quantity
of efficacy for a given GPCR, will be considered. All of
these classes will be discussed in terms of the evidence
for their classification and their possible therapeutic
relevance. As a preface to discussion of these drug
entities, it is useful to discuss the dynamics of the GPCR
systems with which they interact.
GPCR systems
G-protein-coupled receptors are allosteric proteins de-
signed by nature to respond to small ‘drug-like’ mole-
cules (i.e., neurotransmitters) to affect changes in large
protein–protein interaction (receptors and G-pro-
teins). The common currency of this translation of
information is receptor protein conformation. It is
essential to understand three particular properties of
GPCR systems in order to understand how ligands can
function as inverse, protean, and structure-specific ago-
nists. The first is that, like all proteins, receptors can
exist in various conformations. However, in the case of
GPCRs, some of these conformations reveal sequences
in their cytosolic loops, which can then activate G-
proteins to initiate response. These conformations are
referred to as the ‘active state’ (Ra) of the receptor;
correspondingly, the conformation(s) that do not acti-
vate G-proteins are referred to as the ‘inactive state’
(Ri). In the simplest case, one single conformation of
each will be assumed with the two conformations
existing in an equilibrium defined by an ‘allosteric
constant’ (denoted L and defined as [Ra]/[Ri]).
A second property of GPCR systems is that they are
synoptic and interactive. Therefore, it is incorrect to
describe GPCR function simply in terms of the receptor
(two-state theory). Rather, the G-protein is an interac-
tive and essential part of the system. The G-protein
influences the receptor in ways that modify the behav-
ior of the receptor and vice versa. Of particular rele-
vance is the fact that a receptor can spontaneously
interact with G-proteins in the absence of agonist
ligands. Thus, if the affinity of Ri for a G-protein is
denoted Kg (equilibrium association constant), the
affinity of the active state Ra for the same protein is
denoted bKg where b.1. Response emanates from the
hydrolysis of GTP by the G-protein resulting from
activation by Ra. From these elements the simplest
version of a GPCR system can be constructed:
Ri 5
L
Ra 1 G 5
bKg
RaG (1)
It can be seen that such a system defines the possibility
of constitutive activity whereby a response can be
produced by the GPCR system in the absence of an
agonist. The system can be made to produce a response
through stoichiometry of the reactants, namely, Ri and
G. Thus, the constitutive activity (as defined by elevated
levels of [RaG]) can be increased by raising the recep-
tor concentration:
Constitutive Activity 5
bL@Ri#/KG
1 1 bL@Ri#/KG
(2)
where KG is the equilibrium dissociation constant of the
receptor/G-protein complex (KG51/Kg), or by in-
creasing the concentration of G-protein:
Constitutive Activity 5
bL@G#/KG
1 1 L~1 1 b@G#/KG!
(3)
Another way in which constitutive activity can be pro-
duced is through alteration of L, the allosteric constant.
Under normal circumstances, L is a unique molecular
constant for a given receptor (i.e., the energy barrier to
formation of spontaneous active states for some recep-
tors is lower than it is for others), but experimental
methods such as the removal of sodium ions (2, 3) or
point mutation (4–10) can affect L and make receptors
more constitutively active.
Figure 1. Chemical targets for GPCRs. Prior to 1995, the
principal targets were full and partial agonists and antago-
nists. It is predicted that the types of ligands discovered will
increase with increased screening technology. Full agonist:
produces full receptor activation leading to production of the
system maximal response. Partial agonist: produces submaxi-
mal receptor activation leading to production of submaximal
system response and possible blockade of full agonist activa-
tion. Antagonist: produces no physiological response but
rather blocks the response to endogenous or exogenous
agonists. Inverse agonist: functions as an antagonist in non-
constitutively active systems, but has the added property of
actively reducing receptor-mediated constitutive activity of
GPCR systems (response not resulting from agonist activation
but rather spontaneously emanating from the system itself).
Allosteric agonist: functions as an agonist but activates the
receptor through interaction at a site distinct from that of the
endogenous agonist (usually a nonpeptide ligand for a pep-
tide receptor). Allosteric modulator (antagonist): blocks re-
ceptor function but does not necessarily interfere with ligand
receptor interaction (receptor occupancy). Allosteric en-
hancer: potentiates the effects of agonists on the receptor.
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The simple model for GPCR systems can be com-
pleted by adding the interaction of ligand (designated
[A]) to the system to produce a corresponding array of
species ARi, ARa, and ARaG. When the ligand-bound
ensemble is added to the scheme shown in Equation 1
(see also Fig. 2A), the extended ternary complex model
(ETC model) for GPCR systems results (5). A more
thermodynamically complete version of the system al-
lows the inactive receptor Ri to interact with the
G-protein. In terms of thermodynamic modeling, this
must be allowed to occur (11). However, the existence
of an inactive ternary complex comprising ARiG is
largely theoretical. Some examples of this complex can
be found for some receptors (see ref 12 for a review);
however, the thermodynamically complete model for
GPCR systems, termed the cubic ternary complex
model (CTC model; 13–15), requires a greater number
of microaffinity constants than the ETC model and
generally is more complex (see Fig. 2B). The ETC
model can be regarded as a subset of the CTC model
and adequate for GPCR systems for which the interac-
tion of Ri with G-protein is thought to be minimal. For
the purposes of this review, both models yield similar
predictions for GPCR behavior with some minor excep-
tions.
The third relevant property of GPCR systems is an
extension of the first: the production of multiple active
receptor states (that go on to produce response
through interaction with G-proteins). The minimal
requirement for a GPCR model is that one receptor
active state be formed. Thus, in principle, agonists can
induce response by causing enrichment of that single
receptor active state. Under these circumstances, effi-
cacy would then be a matter of the quantity of the active
state produced by the agonist. However, there is no
theoretical constraint on the number of receptor active
states. Even though the ETC and CTC model have both
been referred to as ‘two-state’ models, this is a misno-
mer in that there is the capability within both to be
multi-state models. The two-state aspect of these models
refers only to the unliganded species Ri and Ra. In
principle, the microaffinity constant of the liganded
receptor could be specific for the ligand (through the
values a and g for the ETC model and a, g, and d for
the CTC model; see Fig. 2), i.e., the affinity of the
ligand-bound receptor for G-protein (ARaG) could be
different from the unbound form (RaG). Under these
circumstances, both the ETC and CTC models can
accommodate an infinite number of receptor active
states for agonism.
It is clear that proteins, including GPCRs, can adopt
numerous conformations according to thermal energy
(16, 17). What is not clear is what proportion of these
conformations are capable of activating G-proteins, i.e.,
how many are receptor active states? Amino acid se-
quences have been identified in the intracellular loops
of GPCRs that, when exposed to G-proteins, activate
them (18–20). In fact, small oligopeptide isolated
sequences have been found to activate G-proteins on
their own (21, 22). With this model in mind, it would
suggest that the inactive form of the receptor prevents
access of G-proteins to these sequences, thereby pre-
cluding receptor activation of G-proteins. The corollary
to this is that any disruption of the tertiary structure of
the receptor could expose these activating amino acid
sequences to initiate G-protein activation. On theoret-
ical grounds, it might be expected that there could be
numerous tertiary conformations of the receptor capa-
ble of exposing these intracellular sequences, i.e., there
could be numerous active state conformations of the
receptor. Mutation studies support this idea. For exam-
ple, the substitution of 20 amino acids in position 293
of the a1A-adrenoreceptor produces a constitutively
active receptor—essentially 20 different active state
similar forms of the a1A-adrenoreceptor (4). The pro-
duction of constitutive activity (whereby the receptor
spontaneously adopts an active state and produces
Figure 2. Two models for GPCR systems. The extended
ternary complex (ETC) model (5) assumes that only the
active-state receptor (Ra) can interact with the G-protein
either spontaneously (to form RaG) or through ligand bind-
ing (to form ARaG). The association constants are K (ligand
to receptor) and bKg (receptor to G-protein). L is the
allosteric constant and a, g the modifiers of affinity once the
receptor is active or ligand bound, respectively. The cubic
ternary complex is very similar except it allows the inactive-
state receptor Ri to interact with the G-protein as well
(13–15).
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G-protein activation) through such mutations for re-
ceptors indicates that disruption of receptor tertiary
conformation can expose activating sequences to G-
proteins (10, 23, 24). A general message from these
studies is the possibility of the existence of numerous
active state conformations of GPCR able to initiate
physiological response. The apparent ligand-specific
production of receptor conformations that interact
differently toward other membrane proteins (including
G-proteins), to be discussed later in the context of
ligand-specific agonist efficacy, further suggest the ex-
istence of multiple receptor active states for GPCRs.
The previous discussion has described essentially
three characteristic behaviors of GPCR systems: the
capability to exist in multiple states, the ability of these
states to spontaneously interact with other membrane
proteins, and the possible existence of multiple states
capable of inducing physiological response. To explore
the interaction of ligands with such systems, it is useful
first to discuss the mechanism by which ligands can
influence receptor/G-protein ensembles.
The influence of ligands on GPCR systems
The relative quantities of various protein species exist-
ing in equilibria with each other are governed by the
equilibrium dissociation constants that define their
ratio. Thus, the allosteric constant is defined as [Ra]/
[Ri]. The nature of L is controlled by the molecular
nature of the receptor; thus, for any quantity of Ri there
will be a quantity of Ra governed by the magnitude of
L. However, this can be changed if external forces
perturb the quantity of either one of the species. For
example, if a ligand binds selectively to the Ra species
to form ARa, then the quantity of free Ra is depleted
and the magnitude of L will dictate that more Ra must
be formed at the expense of existing Ri (see Scheme 1).
This can be shown mathematically within the con-
straints of either the ETC or CTC model (Fig. 2). For
example, the concentration of response producing
species (RaG and ARaG) in the presence of a ligand A
in terms of the ETC model is given by Kenakin et al.
(12):
r 5
bL@G#/KG~1 1 ag@A#/KA!
@A#/KA~1 1 aL~1 1 gb@G#/KG!!
1 1 1 L~1 1 b@G#/KG!
(4)
In the absence of agonist ([A]50)
r0 5
bL@G#/KG
1 1 L~1 1 b@G#/KG!
(5)
In the presence and absence of a maximal concentra-
tion of ligand (saturating the receptors; [A] 3 ‘)
r‘ 5
agbL@G#/KG
1 1 aL~1 1 gb@G#/KG!
(6)
The ratio of response producing species in the pres-
ence and absence of ligand is given by:
r‘
r0
5
ag~1 1 L~1 1 b@G#/KG!!
~1 1 aL~1 1 gb@G#/KG!!
(7)
As depicted in Fig. 2, a and g reflect modifiers of the
affinity constant of the receptor for the G-protein when
the receptor is activated and occupied by ligand, re-
spectively. For example, a value of a . 1 indicates a
greater affinity of the ligand for the active-state recep-
tor Ra. It can be seen from Equation 7 that only one
condition will enable a ligand to bind to the GPCR
species in the system and not cause a redistribution of
receptor species. That is if a 5 g 5 1 (the presence of
the ligand on the receptor does not in any way affect
the affinity of the receptor for G-proteins, i.e., the
ligand has no efficacy). If a or g Þ 1, then the ratio of
active-state species will change in the presence of A:
when A is added to the system, the concentrations of
the various species will redistribute. Therefore, the
selective affinity of ligands for various receptor confor-
mations will change the overall distribution of species
in GPCR receptor ensembles and thus, either induce or
inhibit response. This is the basic mechanism of ligand
efficacy and the basis for the molecular nature of
inverse, protean, and ligand-selective agonism.
INVERSE AGONISTS
Inverse agonists were discovered only after the tools
with which they could be detected were created,
namely, constitutively active GPCR systems. Whereas
ligands that depress the basal benzodiazepine receptor
(a non-GPCR) activity had been studied a decade
before (25, 26), true GPCR constitutive activity was first
quantified in recombinant receptor systems where ex-
perimental conditions could be manipulated to pro-
duce constitutive activity. As noted, the ability to spon-
taneously produce an active receptor conformation
(the conformation that activates G-proteins) is defined
by the allosteric constant, a receptor-specific constant
defining the energy barriers to the production of
tertiary conformations. Thus, in natural systems with
defined receptor/G-protein stoichiometry, the amount
of spontaneously formed active-state receptor species
may not be sufficient to demonstrate visible constitutive
receptor activity. This constraint was eliminated by the
introduction of recombinant GPCR systems, which
could experimentally manipulate the relative stoichi-
ometry of receptors and G-proteins.
A classic study by Costa and Herz (2) of NG108–15
cells recombinantly expressing opioid receptors was
instrumental in defining constitutive GPCR activity and
inverse agonism. Costa and Herz (2) produced a system
that responded to the classic opioid agonist (i.e., [D-
Ala2), D-Leu]enkephalin), but also had an elevated
basal response and demonstrated a depression of basal
activity with the peptide ICI 174864 ([N,N9-diallyl-
Tyr1,Aib2,3]Leu5-enkephalin). In this constitutively ac-
tive GPCR system, ICI 174864 depressed the ligand-
independent elevated basal responses and was thus
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defined as an inverse agonist. The simplest mechanism
by which inverse agonism could occur is the selective
affinity of the ligand for the inactive state of the
receptor. Thus, as the ligand binds selectively to Ri, the
receptor species in the system will redistribute. If the
system has RaG present (constitutive activity), then this
species will be depleted as more receptor transforms
into ligand-bound Ri; the result will be a decrease in
constitutive activity.
Inverse agonism is a fairly newly discovered phenom-
enon for GPCR systems. The effect was initially met
with some skepticism since it required the reclassifica-
tion of established antagonists as inverse agonists. Also,
in some systems the trace presence of endogenous
agonists leads to an apparent constitutive activity, which
could then be depressed by simple competitive antag-
onists, i.e., inverse agonism could be an artifact in some
systems. However, the lack of depression of basal re-
sponses to some antagonists (i.e., neutral antagonists)
and the use of such neutral antagonists to block the
effects of inverse agonists clearly indicate that the
phenomenon is real. For example, Costa and Herz (2)
used the neutral antagonist MR 2266 to block the
effects of the positive agonist DADLE and the inverse
agonist ICI 174864, and showed that the potency for
the inhibition of both effects was the same.
After the initial discovery, there was a period when
there was a paucity of data available to judge the
prevalence of inverse agonists in pharmacology. How-
ever, with time has come an increasing number of
reports describing previously classified antagonists as
inverse agonists. This rise coincided with the increased
availability of recombinant and constitutively active
GPCR systems, a prerequisite for the observation of
inverse agonism. Thus, now that more laboratories have
eyes to see inverse agonism, the more it has been seen.
It is still premature to judge the prevalence of inverse
agonism in chemical space. In theoretical terms, there
is reason to believe that all ligands should not possess
efficacy. As described above, for a ligand not to cause
redistribution of GPCR species it must recognize at
least two receptor conformational species as being
identical: Ra and Ri. In a constitutively active system,
this is increased to three species by the presence of
RaG. As shown in Equation 7, the ligand-specific con-
stants a and g must be unity in terms of the ETC model
(and a, g, d in the CTC model) for redistribution not to
occur (i.e., for a ligand to have no efficacy). The
question then is: How often, in thermodynamic terms,
is this likely to occur? Although some studies appear to
support the prediction that most antagonists are in-
verse agonists (i.e., of 23 a1-adrenoreceptor antagonists
of varying structure, all were inverse agonists) (27),
there are clear examples of neutral antagonists in the
literature. The degree of inverse agonism observed
depends on the relative affinity of the inverse agonist
for the various receptor species and the degree of
constitutive activity in the system. Thus, ligands that
only slightly differentiate receptor conformations will
essentially appear to be neutral antagonists, especially
in systems with low levels of constitutive activity.
Although the existence of inverse agonists has been
substantiated in experimental systems, the therapeutic
relevance of this drug class is as yet unknown. It also is
not clear whether negative efficacy would be a desirable
or undesirable property to have in an antagonist mol-
ecule. In the absence of constitutive receptor activity,
an inverse agonist behaves exactly as a simple compet-
itive antagonist. However, if there is constitutive activity
present in the therapeutic system, then, unlike a simple
competitive antagonist, an inverse agonist will depress
the resulting elevated basal response. There are physi-
ological scenarios where this may or may not be advan-
tageous.
Adverse effects of inverse agonists
Inverse agonism has been associated with receptor
up-regulation leading to tolerance to chronic antago-
nism. For example, in treating an ulcer, tolerance to
some histamine H2 receptor antagonists has been
observed (28–30). It has been postulated that chronic
treatment with histamine antagonists results in in-
creased levels of membrane histamine receptors (31).
The ligands shown to cause increases in histamine H2
receptor density—cimetidine and ranitidine—are in-
verse agonists but there is no concomitant increase in
receptor density observed with the neutral antagonist
burimamide (32). In that membrane receptor popula-
tions are not static, but rather are a series of steady
states resulting from receptor synthesis, transport to the
surface, internalization, and degradation, any ligand
that perturbs receptor states theoretically can affect the
steady-state level of the receptor density. For example,
activation by agonists increases phosphorylation of
many receptors and subsequent internalization (33–
35). It has been shown that spontaneous formation of
receptor active states (constitutive activity) leads to
eventual internalization of receptor as well (33, 36).
Possessing equal affinity for both the inactive and active
receptor states, a neutral agonist would not alter flow of
receptor to and from the membrane surface. However,
an inverse agonist could halt the spontaneous cycle of
receptor synthesis, transport, internalization, and deg-
radation at the membrane by selectively stabilizing the
inactive state of the receptor. If this state is more
resistant to phosphorylation and subsequent internal-
ization, then receptor degradation would be slowed in
the face of unaltered receptor synthesis. The extent of
change of steady-state membrane receptors would be a
function of the rates of the various processes synthesiz-
ing, transporting, and internalizing them (37), but
under appropriate conditions elevations of receptor
could occur leading to increased agonist response.
This, in turn, would result in a decrease in the effec-
tiveness of the antagonist. Thus, in this scenario, in-
verse agonism would be an undesirable property (38).
Receptor up-regulation by inverse agonists has been
shown to occur with inverse agonists for histamine H2
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receptors (32), b2-adrenoreceptors (39), and a1-adre-
noreceptors (40). In addition to changes in receptor
density, inverse agonists have also been found to alter
levels of G-protein. Thus, up-regulation of levels of
Gq/11a through 5-HT2C receptors (41) and Gsa through
b2-adrenoreceptors (42) has been obtained with in-
verse agonists for the respective receptors. Presumably
the changes in receptor stimulation of these pathways
leads to secondary effects on G-proteins.
Therapeutic application of inverse agonists
The extent to which inverse agonism could be a ther-
apeutic advantage depends on the role of constitutive
GPCR activity in pathology. One potential therapeutic
area where this might have relevance is cancer. It has
been shown that chronic elevation of second messen-
gers in cells produced by constitutive G-protein activity
can lead to cell transformation (43–45). For example,
receptors such as the a1-adrenoreceptor have been
shown to be agonist-independent proto-oncogenes
(46). Constitutive GPCR activity leading to chronic
elevation of cell metabolism may also have a role in
promoting the growth of tumors. There are examples
of high levels of expression of specific GPCRs in tumor
cells; it has been shown that endogenous ligands for
these receptors are present at high levels in the tumor
cells (self-regulation) and that they have proliferative
properties. There also is evidence to show that inhibi-
tion of the cellular effects of these ligands can inhibit
tumor growth.
One such receptor is vasoactive intestinal peptide
receptor (VIP). Receptors for VIP are found in high
density in a number of tumors (47–55); see Table 1. In
fact, these high levels of VIP receptors can be used to
image tumors through binding of 123I-VIP (55) and
123I-labeled octreotide (VIP ligand; 57, 58) binding.
The relevance of high levels of VIP GPCR activity on
tumors relates to the fact that this peptide promotes
growth and proliferation of normal and malignant cells
(59–63). Inhibition of VIP function in these cells leads
to a decrease in cancer growth (64, 65); see Fig. 3. The
relevant question for inverse agonism is, to what extent
can the VIP-mediated proliferation be attributed to
constitutive VIP GPCR activity? Many of these tumors
have high levels of VIP, and it has been suggested that
VIP secretion from these tumors regulates VIP receptor
expression on the same cells (66). Certainly the high
levels of VIP receptor present on the tumor cell mem-
brane would make them extremely sensitive to low
levels of released VIP. However, the sheer magnitude of
the receptor expression suggests that constitutive re-
ceptor activity may also play a role in the pathology.
There are differences in the proclivity with which
different GPCRs spontaneously produce an active-state
receptor (with corresponding constitutive activity).
Some receptors have a low-energy barrier for the for-
mation of Ra (i.e., human calcitonin, chemokine
CCR5, neuropeptide Y types 2 and 4) whereas others,
such as NPY1, do not readily produce constitutive
activity (67); the difference lies in the magnitude of the
allosteric constant, L. However, since the definition of
L is the ratio of Ra to Ri (L5[Ra]/[Ri]), then irrespec-
tive of the magnitude of L, a 1000- to 10,000-fold
increase in the number of receptors will lead to a
corresponding 1000- to 10,000-fold increase in the
number of spontaneously existing active-state recep-
tors. Thus, the magnitude of L for VIP would need to
be exceedingly small to prevent such high levels of
receptor from producing constitutive activity.
Another peptide of interest in cancer is bombesin.
Bombesin, gastrin-releasing peptide, and VIP are re-
lated in that VIP may induce the release of bombesin/
GRP in small cell lung cancer (65, 68). Bombesin-like
peptides are potent mitogens, and a role has been
proposed for them in oncogenesis and/or proliferation
of malignant cells (69). Bombesin/gastrin-releasing
peptides are found in high levels in small cell lung
TABLE 1. VIP receptors in tumors and normal cells
Cells Bmax (sites/cell)
a
Multiple of
platelet
cell density
Platelets 2.1 6 0.3 3 103 1
A431b 1.6 6 0.3 3 106 (high-affinity sites) 8003
9.7 6 0.4 3 106 (low-affinity sites) 46203
COLO
320c 1.9 6 0.4 3 108 (high-affinity sites) 90,5003
7.3 6 0.8 3 106 (low-affinity sites) 347,6003
HT29c 1.2 6 0.5 3 108 (high-affinity sites) 57003
6.9 6 0.9 3 106 (low-affinity sites) 32,8503
PANC1d 2.1 6 0.4 3 108 (high-affinity sites) 100,0003
6.9 6 0.8 3 106 (low-affinity sites) 32,8503
a Binding of 125I-labeled VIP. b Epidermoid mammary carci-
noma. c Adrenocarcinoma. d Pancreatic epitheloid carci-
noma. From ref 56.
Figure 3. Effects of VIP and peptide fragment octreotide on
tumor growth as measured by 3H-thymidine-incorporation
(cpm 3 103). Abscissae are logarithms of molar concentra-
tion of vasoactive intestinal peptide (VIP) or octreotide.
Redrawn from ref 56 with permission.
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carcinomas, suggesting that these could be autocrine
factors for cancer growth (70–72). As with VIP, block-
ade of bombesin activity through monoclonal antibod-
ies attenuates cancer growth (69).
Inverse agonists would both block the effects of
humoral activation of these receptors on cancer cells
(i.e., secreted VIP, bombesin) and constitutive activity
in the tumor due to either receptor over-expression
and/or mutation. Whereas the effect would be cyto-
static rather than a cytocidal (tumor death would not
be achieved), a reduction in tumor cell metabolic
activity could be a useful adjunct to chemotherapy.
Certain disease states may be treated effectively only
with inverse agonists. These are instances where the
pathological entity is a constitutively active GPCR,
which produces physiological response in the absence
of endogenous agonists. For example, certain patholog-
ical mutations lead to constitutively active GPCRs,
which in turn result in diseases such as retinitis pigmen-
tosa and hyperthyroidism (see review by Spiegel, ref
73). Constitutively active GPCRs may also be important
in autoimmune diseases (see review by de Ligt et al., ref
74). Viral infection also can lead to constitutively active
GPCR pathology. For example, infection with Kaposi’s
sarcoma-associated herpes virus leads to expression of a
constitutive chemokine receptor, which in turn elevates
IP3 to lead to cell proliferation and continued viral
replication (75, 76).
In general, it still is not clear to what extent GPCR
constitutive activity plays a role in pathology. However,
it is known that receptors and enzymes levels change in
conditions of trauma (hypoxia, ischemia, physical dam-
age), disease (inflammation, viral or bacterial infec-
tion), or development (78, 79). Although, in general,
solid examples of constitutive receptor activity playing a
role in disease are sparse, with the classification of
clinically used inverse agonists, the relationship be-
tween negative efficacy and therapeutic utility should
become clearer. Along with clarification of the role of
constitutively active GPCRs in pathophysiology will
come a measure of the value of inverse agonists in
therapy.
PROTEAN AGONISTS
A unique reversal of drug activity, based on the notion
that some agonists may produce an active receptor
conformation of lower efficacy than the spontaneously
formed one has been predicted on theoretical grounds
(80, 81). These kinds of ligands were given the name
protean agonists after Proteus, the Greek god who
could change shape and appearance at will. In this case,
the reversal from positive to negative agonism is pro-
tean. If a given agonist produces a receptor active state
that is less efficacious (to be denoted [Ra9]) than the
spontaneously formed one (denoted [Ra]), then in
systems that are quiescent (no constitutive activity), the
ligand would produce excitation by virtue of changing
the predominant Ri into Ra9. However, if the system
were constitutively active (significant amount of Ra),
then the ligand would reduce the activity by changing
Ra to Ra9. Therefore, in quiescent systems the ligand
would be a positive agonist and in constitutively active
systems it would be an inverse agonist. Presently it is not
clear what therapeutic relevance such an agonist would
have except perhaps to set the level of stimulation of a
given system to a constant level. Thus, if pathology
produced constitutive activity to create an overstimula-
tion of the system or if the endogenous stimulus to the
system were to be diminished by pathology, then a
protean agonist would be useful if the maximal effect of
the agonist was appropriate.
On the other hand, there is a considerable theoreti-
cal interest in protean ligands since they can act as a
looking glass into agonist-specific receptor active states.
Thus, the observation of protean agonism would be
presumptive evidence that the ligand in question pro-
duces a receptor active state of lower intrinsic efficacy
than the naturally occurring constitutively active state.
It is worth considering the experimental conditions
under which such protean agonism would be observed.
The starting point is to have a ligand that produces a
positive agonist response in a quiescent (nonconstitu-
tively active) receptor system. It might be supposed that
the agonism should be partial (in keeping with a less
efficacious ligand-bound active state). However, satura-
tion of system stimulus-response mechanisms might
allow low efficacy agonists to produce the full system
response; therefore, partial agonism may not be a
prerequisite. The next step is to observe the effect of
ligand in a system where the receptor is made to
spontaneously form the natural active state. For exam-
ple, Fig. 4A shows the effect of increasing the magni-
tude of the allosteric constant L (as might be produced
by removal of sodium ions) in a hypothetical GPCR
system. The ligand is a theoretical drug that promotes
the formation of the natural active state (a5100) but
forms a ligand bound species that has a lower affinity
for the G-protein than the natural active state (ARa has
a lower affinity for G than does Ra; g50.01). Calcula-
tions with the CTC model show that in the quiescent
system (L50.01), the ligand is a positive agonist.
Changing L from 0.01 to 0.3 elevates the basal response
of the system and causes the ligand to demonstrate
inverse agonism. Another way to produce constitutive
activity is by increasing the amount of G-protein avail-
able to interact with the receptor (Equation 3). Under
these circumstances, a similar ligand (g50.03) will
demonstrate protean agonism as well (Fig. 4B). An-
other condition that may yield protean agonism is when
the receptor reactivity to the G-protein changes. For
example, Fig. 4C shows that if the affinity of both Ri and
Ra is reduced for the G-protein (KG increases), as might
be produced by desensitization, an inversion of ago-
nism for the same ligand would be observed. Note how
in this case the basal activity is not altered.
There have been experimentally observed instances
of protean agonism for b2-adrenoreceptor ligands. For
example, dichloroisoproterenol (DCI) is a positive par-
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tial agonist for b2-adrenoreceptors transfected into sf9
cells. Upon desensitization of the system through pro-
longed treatment with the full agonist isoproterenol (as
depicted in the simulation Fig. 4C), DCI produces
inverse agonism (82). Figure 5 shows the effects of
three b2-adrenoreceptor ligands on transfected sf9
whole cells; DCI, labetalol, and pindolol all produce
increases in cyclic AMP (positive agonism). However,
when membranes were made from the same cells, the
system became constitutively active (due to removal of
GTP) and, under these circumstances, these same
ligands produced depression of basal cyclic AMP levels
(inverse agonism) (83). It is not clear to what extent
low efficacy receptor conformations are responsible for
the experimentally observed protean agonism. How-
ever, observation of the phenomenon is suggestive of
selective receptor states and this may be a useful tool
for discovery of ligand-specific receptor active-states.
LIGAND-SPECIFIC RECEPTOR ACTIVE STATES
Numerous lines of experimental evidence indicate that
all agonists do not produce the same active state of
GPCRs. One of the most compelling findings is the
reversal of relative potency of agonists for receptors
that activate more than one stimulus-response element.
For example, the human 5-HT2C receptor is coupled to
two separate response pathways in CHO cells: phospho-
lipase C-mediated inositol phosphate accumulation (IP
accumulation) and phospholipase A2-mediated arachi-
donic acid release (AA release). The agonist (6)-1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI) pro-
duces a higher maximal stimulation than the 5-HT
agonist quipazine for arachidonic acid release (77).
Since maximal response is dependent only on efficacy,
this indicates that DOI has a greater efficacy than
quipazine for AA release. In contrast, the efficacies of
the two agonists are reversed for the IP accumulation
where quipazine has the greater efficacy. This cannot
be explained by a uniform active-state receptor inter-
acting with the two pathways identically for the two
agonists, but rather it suggests that the active state
formed by DOI (arachidonic release-preferring) is dif-
ferent from that produced by quipazine (IP accumula-
tion-preferring). Similar reversals of efficacy have been
reported for PACAP (pituitary adenylate cyclase-activat-
ing polypeptide) receptors (84), dopamine D2 recep-
tors (85) and Drosophila tyramine receptors (86). A
striking reversal of relative potency of substance P
analogs on neurokinin-1 receptors has been reported
(87). Thus, whereas substance P is 2.13 more potent
than the analog [P3
Emet(O2) (11)SP for producing
cyclic AMP through NK-1 receptor activation, it is
0.113 less potent than the analog for producing phos-
phoinositol hydrolysis through activation of the same
receptor. Whereas no reversals in relative efficacy for
agonists was found in a study of CB1 cannabinoid
receptors (known to activate both Gs and Gi protein),
marked discontinuities in the activity of agonists were
observed indicating that some agonists produced con-
formations that favored one of the two G-proteins while
others did not (88).
Differential activation of G-proteins by receptors
(referred to as stimulus trafficking; refs 89–91) cannot
be accommodated by a mechanism whereby one single
receptor active state produced by all agonists interacts
with G-proteins. Although differential stimulus pathway
activation can occur through strength of signal type of
mechanism (i.e., a highly efficacious agonist may acti-
vate two pathways whereas a weaker agonist may acti-
Figure 4. Three theoretical condi-
tions that promote protean ago-
nism. Simulation made with cubic
ternary complex model (Fig. 2B)
for a ligand with a 5 100, g 5
0.01, d 5 0.1. [R] 5 100. A) [G] 5
100, KG 5 30, b 5 10. The system
ranges from quiescent (L50.01)
to constitutively active (L50.3).
B) Ligand with a 5 100, g 5 0.03;
L 5 0.1; [G] increased from a
value of 10 to 250. C) Ligand with
a 5 100, g 5 0.03, L 5 0.1;
receptor ‘desensitized’; [G] 5 500, interaction of receptor and G-protein efficient (KG50.003) to inefficient (KG530).
Figure 5. Experimentally observed protean agonism. Sf9 cells
transfected with b2-adrenoreceptor. Gray bars represent
whole cells (not constitutively active due to presence of
intracellular GTP); ligands produce stimulation of cyclic
AMP. Membranes from same cells are constitutively active;
the same ligands produce inverse agonism (filled bars). Data
from ref 83 with permission; figure from ref 1 with permis-
sion.
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vate only the more sensitive one), reversal of relative
activity cannot be explained in this manner. Rather, the
two G-proteins involved must see different conforma-
tions. It would be expected that different conforma-
tions of the receptor would have differential activation
reactivities to different G-proteins since it is known that
different areas of the cytosolic loops on receptors
activate different G-proteins (92, 93). It would not be
expected that different tertiary conformations of the
receptor would expose these different G-protein-acti-
vating sequences in an identical manner.
Stimulus trafficking can be detected in specially
designed recombinant GPCR systems. Referred to as
stimulus-biased assay systems (94), these are hosts with
identical cellular backgrounds except for the enrich-
ment of a single Ga subunit. For example, human
calcitonin receptors are pleiotropic with respect to the
G-proteins with which they can interact (Gs, Gq, Gi; ref
95). Transfection of human calcitonin receptors (type
2, denoted hCTR2) into wild-type HEK 293 cells and
HEK cells stably transfected with enriched populations
of Ga subunits show striking differences in relative
agonist potencies. Figure 6A shows that not only does
the relative potency of eight calcitonin agonists on
hCTR2, transfected in wild-type cells, and HEK cells
stably enriched with Gas subunit change, but so does
their rank order of potency. Figure 6B, C shows dose-
response curves to rat amylin and porcine calcitonin in
wild-type cells and Gas-enriched cells, respectively. It
can be seen that the relative potency of the agonists
changes from 4.6 to 84 with Gas-enrichment, a finding
that cannot be accommodated by the assumption that
both agonists produce the same receptor active state
(94). Rather ,it suggests that porcine calcitonin pro-
duces a conformation more conducive to using Gs than
does amylin.
Other experimental approaches have furnished data
to indicate differential G-protein activation by different
agonists produced by agonist-specific receptor confor-
mations. For example, the kinetics of adenylate cyclase
activity in the presence of limiting GTP concentrations
indicates a differential rate of heterotrimer dissociation
for different b2-adrenoreceptor agonists (96). Similarly,
whereas the efficacy of b2-adrenoreceptor agonists for
promoting GTP hydrolysis correlates well for the effi-
cacy of the agonists for stimulating adenylate cyclase,
the same is not true for the hydrolysis of inosine
triphosphate. The differences in the ability of different
agonists to hydrolyze GTP vs. ITP suggest that different
receptor active states are produced (97).
There are still other lines of evidence to suggest that
agonists produce ligand-specific receptor conforma-
tions. Selective mutations of dopamine D2 receptors
caused selective abolition of receptor/G-protein activa-
tion by dopamine but not other dopamine agonists.
This suggests that these agonists produce different
receptor conformations interacting with G-protein
(98). Studies of the receptor desensitizing effects of
different agonists also indicate the production of li-
gand-specific receptor conformations. For example, it
would be expected that the relative propensity of
agonists to induce desensitization would parallel their
relative efficacies. This was shown to be generally true
for m opioid receptor agonists, with the notable excep-
tion of methadone and L-a-acetyl methadone. These
latter agonists produced disproportionate desensitiza-
tion and receptor phosphorylation, suggesting differ-
ent receptor conformational changes (99). Similarly,
methadone and buprenorphine have been shown to
demonstrate different desensitizing properties from
morphine on m opioid receptors (100). In other studies
of recovery from desensitization, it has been shown that
agonists appear to produce different conformations.
Thus, whereas the recovery from prolonged activation
of 5-HT3 receptor with partial agonists is mono-expo-
nential, it is sigmoidal (indicating 3 steps and 4 states)
with full agonists (101).
The effects of agonists on receptor internalization
also have furnished interesting data regarding ligand-
Figure 6. Relative potency of calcitonin receptor agonists in
wild-type and stimulus-biased GPCR systems. A) pEC50 (2log
of the molar concentration producing half maximal stimula-
tion) for calcium mobilization (n53) for 8 agonists (code
shown in box: CAL5calcitonin, R5rat, H5human, E5eel,
P5porcine, C5chicken, S5salmon) on calcitonin receptors
(hCTR2) transfected into wild-type HEK293 cells (top bar)
and HEK293 cells stably enriched with Gas subunit (bottom
bar). Change in pEC50 shown for each agonist by lines joining
the points. B) Dose-response curves (calcium mobilization as
measured by fluorescence) to porcine calcitonin (open cir-
cles) and rat amylin (filled circles) in wild-type HEK293 cells.
The relative potency of calcitonin to amylin is 4.6. C) Relative
potency of the same agonists as shown in panel B in Gas-
enriched stimulus-biased host cells. The relative potency is
now 84. Data for panel A previously unpublished by Chris
Watson, GlaxoWellcome Research, panels B and C from ref 1
with permission.
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specific receptor conformation. Here it can clearly be
shown that the simple strength of receptor stimulation
can be differentiated from the ability of ligands to
induce receptor internalization. For example, the cho-
lecystokinin (CCK) receptor antagonist D-Tyr-Gly-
[(Nle28,31,D-Trp30)cholecystokinin-26 –32]-phenethyl
ester does not produce receptor stimulation but rather
blocks CCK responses. This antagonist also produces
profound receptor internalization (102). Similarly,
whereas enkephalins and morphine produce stimula-
tion of d and m opioid receptors, enkephalins induce
rapid receptor internalization whereas morphine does
not (103). These data indicate that the conformations
that lead to response are not necessarily the same as
those that induce receptor internalization. It also sug-
gests that different agonists produce receptor confor-
mations with differential propensity to internalize.
In conclusion, diverse experimental approaches have
provided evidence that ligands can stabilize different
receptor conformations. Some of these conformations
relate to receptor signaling, whereas others may relate
to receptor sensitivity to endogenous agonist or pres-
ence on the cell membrane. The challenge is to exploit
this behavior for therapeutic advantage.
Ligand-selective conformations and therapeutic
utility: the quality of efficacy
Historically, receptors have been thought of operation-
ally in terms of ‘on-off’ switches. In this context, efficacy
was considered to be the ‘on’ position and the only
gradation available in this scheme was degree of
strength. With the possibility of agonist-selective activa-
tion of receptors and the definition of efficacy as a
change in the behavior of receptors to their hosts
comes the capacity to control the ‘quality’ of efficacy as
well.
In terms of signaling, a common quest in drug
discovery is to obtain ligands with a subset of activity for
a given endogenous ligand receptor system. Histori-
cally, the method for doing this was through discovery
of receptor subtypes. Thus, whereas epinephrine has a
plethora of metabolic activities in the body mediated by
b-adrenoreceptors, selective agonist stimulation of only
the b2-adrenoreceptor subtype provides useful therapy
for asthma. Stimulation of the receptor subtype reduces
the spectrum of metabolic responses produced by the
general receptor family. If it is accepted that different
receptor conformations most likely reveal different
portions of the intracellular cytosolic loops of GPCRs,
then ligand selective receptor conformations can lead
to further selective directing of activation to G-proteins
(trafficking of receptor stimulus). Such trafficking has
been shown in natural and recombinant systems. For
receptors that produce pleiotropic activation of multi-
ple G-proteins, this would limit the signaling pathway
activated by the particular ligand and thus confer
further selectivity to the agonist (see Fig. 7).
It is not obvious how knowledge of ligand selective
efficacy would be applied to drug discovery. However, it
could be useful to classify agonists on the basis of
stimulus-response coupling as knowledge for retrospec-
tive analysis. Currently, agonists are all assumed uni-
formly to stimulate receptors and differ only on a
spectrum of strength of signal. Separating agonists, in
terms of the stimulus-pathways that they preferentially
activate, may offer insights into preferred profiles of
agonism as compounds are progressed from screening
assays into therapeutically oriented secondary assays
(104).
There are other realms of ligand-selective receptor
conformation selection that may have therapeutic util-
ity. For example, ligands that selectively induce recep-
tor internalization may have great utility in the preven-
tion of HIV-1 infection through chemokine receptor
fusion. Ligands that cause internalization of CXCR4
(105, 106) or CCR5 (107, 108) have been shown to
protect against HIV-1 infection in vitro. The selective
removal of chemokine receptor from the cell surface
could be superior to blocking chemokine receptor
interaction with HIV viral coat proteins because it
would circumvent possible rapid emergence of resistant
HIV variants through therapeutic pressure and muta-
tion (109–111).
There are other realms where differential conforma-
tions leading to differences in receptor disposition
could be useful therapeutically. For example, ligand-
selective bias in the production of receptor desensitiza-
tion could be beneficial in treatment of tolerance (99,
100). Similarly, receptor dimerization may be impli-
cated in numerous areas including HIV-1 infection
(112, 113) and the function of cannabinoid receptors
(114), GABAB receptors (115–118), adenosine A1 re-
ceptors (119), d-opioid receptors (120), b2-adrenore-
ceptors (121), and calcium-sensing receptors (122–
124). Ligands that induce selective conformations
Figure 7. Schematic representation of the relative selection of
stimulus pathways for receptors as a generic family is divided
into subtypes and then each subtype is allowed to produce
different active conformations that preferentially interact
with different G-proteins; stimulus pathways are restricted.
From ref 104 with permission.
607AGONIST EFFICACY AND RECEPTOR CONFORMATION
Downloaded from www.fasebj.org by Univ of North Carolina Health Sciences Library (152.2.71.222) on June 07, 2018. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 598-611.
affecting dimerization may produce unique effects not
necessarily associated with direct receptor signaling.
Finally, it is becoming evident that GPCRs can asso-
ciate with other membrane proteins to change their
affinities to ligands and reactivities toward G-proteins.
For example, receptor activity-modifying proteins can
change the phenotype of calcitonin gene-related pep-
tide, adrenomedullin receptors, and calcitonin recep-
tors (125–129). Similarly, GPCRs are known to interact
with other accessory proteins such as PDZ domain-
containing proteins. Thus, b2-adrenoreceptors interact
with Na1/H1-exchanger regulatory factor (130) and
5-HT2C receptors with MUPP1 (a multi-PDZ domain
protein with no currently known function (131). Again,
as with desensitization, dimerization, and internaliza-
tion, these receptor functions could, in theory, be
regulated differentially by different ligand-induced re-
ceptor conformations to change receptor function.
This could lead to another dimension in control of the
quality of ligand efficacy.
CONCLUSIONS
This review describes three apparently separate phe-
nomena—inverse agonism, protean agonism, and dif-
ferent types of positive agonism—in terms of a single
mechanism of action, namely, the interaction of differ-
ent receptor conformations (some spontaneously
formed and some ligand directed) with G-proteins. It
can be seen that such a system has a vastly increased
range of adjustment over one in which a single acti-
vated receptor interacts with G-proteins on a scale of
strength of signal. In this scheme, the stoichiometries
of cellular components can adjust GPCR system set
points and sensitivities; ligands theoretically can bias
such systems in a multitude of ways. The challenge for
the next millennium in drug discovery and receptor
pharmacology will be to exploit ligand bias in these
complex systems for therapeutic advantage.
I wish to thank Mrs. Donna McGhee for expert preparation
of this manuscript.
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